20/20 Biolabs, Inc. (AIDX)
| Market Cap | 3.51M |
| Revenue (ttm) | 2.04M +2.7% |
| Net Income | -7.12M |
| EPS | -1.00 |
| Shares Out | 12.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 274,856 |
| Open | 0.3131 |
| Previous Close | 0.3131 |
| Day's Range | 0.2737 - 0.3131 |
| 52-Week Range | 0.2751 - 50.0000 |
| Beta | -0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 15, 2026 |
About AIDX
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company w... [Read more]
Financial Performance
In 2025, 20/20 Biolabs's revenue was $2.05 million, an increase of 16.71% compared to the previous year's $1.75 million. Losses were -$3.74 million, -32.65% less than in 2024.
Financial StatementsNews
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Compan...
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer...
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
CEO Jonathan Cohen to Detail the Company's Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path t...
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to...
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Ti...
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/2...
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) -- 20/20 B...
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access...
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biola...
20/20 BioLabs develops contingency plans to establish Ebola, Hantavirus
20/20 Biolabs (AIDX) announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by…
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (...
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March...
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detecti...
20/20 BioLabs enters licensing agreement with University of South Carolina
20/20 BioLabs (AIDX) announced that it has entered into an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm developed by a team head...
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs' AI-Enabled Multi-Cancer Early Detect...
20/20 BioLabs initiated with a Buy at Maxim
Maxim initiated coverage of 20/20 BioLabs (AIDX) with a Buy rating and $5 price target
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cance...
20/20 BioLabs files to sell 10.1M shares of common stock for holders
17:33 EDT 20/20 BioLabs (AIDX) files to sell 10.1M shares of common stock for holders
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Sig...
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest
20/20 BioLabs (AIDX) announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health to procure…
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest ™ Multi-Cancer Early Detection Blood Test
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AID...
20/20 BioLabs enters exclusive technology license, access agreement with Rokit
20/20 BioLabs (AIDX) announced that it has entered into an exclusive U.S. technology license and access agreement with Rokit Healthcare. Under the agreement, 20/20 will integrate Rokit’s proprietary c...
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 ...